Lisa G. Barber

Dell Children's Medical Center of Central Texas — United States

Medicine · Health Sciences

26h-index2.3kcitations72works2.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Veterinary Oncology Research(50), Virus-based gene therapy research(24), Sarcoma Diagnosis and Treatment(22), Infectious Diseases and Mycology(11), Cytomegalovirus and herpesvirus research(5)

Publications72 total

Divergent Clinical Courses in Biopsy‐Proven Pulmonary Interstitial Glycogenosis: A Case Series
Pediatric Pulmonology·2026
Divergent Clinical Courses in Biopsy-Proven Pulmonary Interstitial Glycogenosis: A Case Series
2025Open Access
Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2
Molecular Therapy·2025· 7 cited
Effects of a high‐protein, increased‐fibre, dry diet supplemented with omega‐3 fatty acids on quality of life in dogs undergoing chemotherapy
Veterinary and Comparative Oncology·2023Open Access
Data from NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma
2023Open Access
Supplementary Figure 2 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 1 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 3 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Figure 1 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 1 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Data from NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma
2023Open Access
Supplementary Figure 1 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Data from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 2 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Data from NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma
2023Open Access
Supplementary Table 4 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 3 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 2 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 4 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Data from NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Frances S. Shofer(7), David M. Vail(6), Cheryl A. London(6), Amy K. LeBlanc(6), Karin U. Sørenmo(6), Craig A. Clifford(5), Jim Egan(5), Andrew J. Fox(5), Chand Khanna(4), Melissa Paoloni(4), Joyce Lomax(4), Abdul K. Deiraniya(4), Andrew Turner(4), Ashley Woodcock(4), Christina Mazcko(4), Heather Wilson‐Robles(4), P.C. Griessmayr(4), Kristen Weishaar(4), Corey Saba(4), Anne C. Avery(3)